Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 772 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sickle Cell Anaemia Clear all
Recruiting Phase 2 Interventional

Cognitive Remediation Intervention to Prepare for Transition of Care

NCT05336201
View directory record Official record
Conditions
Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills
Interventions
CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

NCT04536792
View directory record Official record
Conditions
Healthy Volunteers, Anemia, Sickle Cell
Interventions
AG-946, AG-946 Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 20, 2026, 5:03 PM EDT
Terminated Phase 1 Interventional

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

NCT03978156
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Dronabinol 2.5 MG, Microcrystalline cellulose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 20, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

NCT03587272
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, low dose total body irradiation, Sirolimus
Drug
Lead sponsor
Robert Nickel
Other
Eligibility
2 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS)

NCT02990598
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

NCT01419977
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 20, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease

NCT06944067
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Withdrawn Phase 4 Interventional

Assessment of Opioid Analgesia in Sickle Cell

NCT00513864
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Dextromethorphan, Codeine, Morphine
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
7 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 20, 2026, 5:03 PM EDT
Completed No phase listed Observational

Improving Sickle Cell Disease (SCD) Care Using Web-based Guidelines

NCT03037021
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
15 Years to 45 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 20, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

The Impact of Oxidative Stress on Erythrocyte Biology

NCT04028700
View directory record Official record
Conditions
Sickle Cell Disease Without Crisis
Interventions
G6PD Deficient Red Blood Cell Transfusion, Non-G6PD deficient Red Blood Cell Transfusion
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Not applicable Interventional

The Feasibility of the Pray Until Something Happens (PUSH) Intervention-OUTPATIENT

NCT06580067
View directory record Official record
Conditions
Sickle Cell Disease, Stress, Pain
Interventions
Pray Until Something Happens (PUSH), Self-monitoring
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

NCT01119833
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
Interventions
GMI-1070, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
12 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Berkeley, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Results available

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

NCT00744692
View directory record Official record
Conditions
Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies, Inborn Errors of Metabolism, Sickle Cell, Thalassemia, Lysosomal Storage Disease
Interventions
Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning
Biological · Drug
Lead sponsor
Duke University
Other
Eligibility
Up to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders

NCT00005783
View directory record Official record
Conditions
Hemoglobin SC Disease, Sickle Cell Anemia
Interventions
Recombinant-methionyl human stem cell factor
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 4 Interventional

Low Dose Ketamine and Acute Pain Crisis

NCT04330183
View directory record Official record
Conditions
Sickle Cell Crisis
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 20, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

NCT05170412
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 120 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Active, not recruiting Not applicable Interventional

Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease

NCT05758766
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plant-based omega-3-FA
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

NCT01048905
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Disease, Thalassemia
Interventions
L-Glutamine
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
4 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 20, 2026, 5:03 PM EDT
Withdrawn Phase 1 Interventional

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031
View directory record Official record
Conditions
Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
5 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients

NCT00029731
View directory record Official record
Conditions
Anemia, Sickle Cell, Pneumonia
Interventions
Arginine hydrochloride
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 20, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional

Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis

NCT00142051
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
nitric oxide, oxygen
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 22 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 20, 2026, 5:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Sampling for Research Related to Sickle Cell Disease

NCT00542230
View directory record Official record
Conditions
Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

NCT00235391
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 20, 2026, 5:03 PM EDT